Early neuropsychological adverse events after switching from PI/r to dolutegravir could be related to hyperthyroidism in patients under levothyroxine Drug-drug interactions are a major problem in the treatment of HIV-infected patients. They mainly concern protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors, which are metabolized by the cytochrome P-450 enzyme system [1] . Ritonavir is known as both a cytochrome P-450 inhibitor and an inductor of glucuronidation, and could affect plasma concentrations of others drugs metabolized through these pathways [2] . We report 2 patients treated with levothyroxine at the same dose for several years with stable TSH levels, who developed clinical and biological hyperthyroidism following a switch from ritonavirboosted PIs to dolutegravir-based HAART. Nervousness, anxiety, irritability and insomnia are clinical symptoms of hyperthyroidism but have also been described as side effects of dolutegravir [3] . However, in our patients, these effects were more probably related to hyperthyroidism, due to decreased inactivation of levothyroxine secondary to the discontinuation of ritonavir-boosted PIs. Furthermore, clinical symptoms and decreased TSH serum values were both resolved after a levothyroxine dose reduction of 40% to 50%. Indeed, levothyroxine is metabolized by deiodination and glucuronidation, and the induction of glucuronidation by ritonavir leads to increased elimination of levothyroxine and a need for higher daily doses [4] . Cases of hypothyroidism have been reported after introduction of ritonavir-boosted PIs in patients receiving levothyroxine [2] . In contrast, dolutegravir, which is a HIV-1 integrase strand transfer inhibitor primarily metabolized by UDP-glucuronosyltransferase (UGT) 1A1 and cytochrome P450 3A4, is not considered as an inhibitor of CYP or UGT enzymes at clinically relevant concentrations [5] . Therefore, drug-drug interactions with dolutegravir are minimal, as it has little ability to alter drug-metabolizing enzymes. To the best of our knowledge, no interaction between dolutegravir and levothyroxine has previously been described. Early discontinuation of dolutegravir-based regimens due to neuropsychiatric adverse events such as insomnia or irritability have been reported [3] . Clinicians should be conscious that these side effects could be related to hyperthyroidism due to a high dose of levothyroxine in patients previously treated with levothyroxine and a ritonavir boosted PI-based regimen.
In conclusion, patients previously treated with levothyroxine who switch from ritonavir boosted PIs to antiretroviral-based HAART with minimal drug interaction potential, such as dolutegravir, may require an adjustment of their dose of levothyroxine in order to prevent hyperthyroidism due to impaired elimination of levothyroxine without ritonavir.
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